We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




Innovative Test Improves Assessment of Patients with Mild Traumatic Brain Injury

By LabMedica International staff writers
Posted on 29 May 2024

Traumatic brain injury (TBI) occurs when external mechanical energy is transferred to brain tissue, causing cellular damage, dysfunction, and dysregulation. More...

It is a significant public health issue, being a leading cause of death and disability globally, with approximately 69 million people affected each year. For clinicians assessing these patients, it is crucial to quickly ascertain the presence or absence of potentially life-threatening hemorrhages and neurological complications. TBI severity is evaluated using the Glasgow Coma Scale (GCS) and categorized as mild, moderate, or severe. Mild traumatic brain injuries (mTBI) are the most common, comprising 70-90% of all TBI cases, and they are the least likely to lead to acute medical emergencies. It is noted that about 90% of mTBI patients who receive computed tomography (CT) scans show no abnormal findings. Despite this, an estimated 82% of all TBI patients are scanned, many of which could potentially be unnecessary. These scans not only increase the time to diagnose but also expose patients to radiation and utilize significant resources from already strained emergency departments (ED). Now, an innovative test aims to improve the assessment of patients with mTBI.

The VIDAS® TBI (GFAP, UCH-L1) from bioMérieux (Marcy-l’Étoile, France) is a serum-based test to support the assessment of patients with mTBI, including concussion. The assay uses a unique combination of the biomarkers GFAP and UCH-L1, proteins that enter circulation following cellular injury. When used in conjunction with clinical information, VIDAS® TBI (GFAP, UCH-L1) results can aid clinicians in determining the need for CT imaging of the head in adult patients (18 years or older), presenting within a large testing window of up to 12 hours after injury, and help shorten ED workup time. A negative test result assists in determining the need for a CT-scan by predicting the absence of ICL. VIDAS® TBI (GFAP, UCH-L1) is available on VIDAS® 3 and VIDAS® KUBE™ immunoanalyzers, offering on-demand automated testing 24/7. bioMérieux has received the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1) and has planned the assay’s commercial launch for the second half of 2024 in the United States. VIDAS® TBI (GFAP, UCH-L1) is also CE-marked and commercialized in selected European, North African and South American countries.

“Securing FDA clearance for the VIDAS® TBI (GFAP, UCH-L1), marks another significant milestone in our journey toward innovative solutions for our customers and improving patient outcomes,” said Colin Hill, General Manager and Head of Clinical Operations, North America. “This enables clinicians to confidently perform fast, efficient triage for mTBI’s, resulting in faster and more informed decisions for personalized treatment of patients.”

“In keeping with the legacy of bioMérieux, we remain committed to developing diagnostic solutions that will improve the delivery of healthcare, have a positive societal impact, and help make the world a healthier place,” said Dr. Charles K. Cooper, Executive Vice President and Chief Medical Officer. “In recognizing the enormity of traumatic brain injury, the VIDAS® TBI (GFAP, UCH-L1) assay contributes to the advancement of current practices in disease evaluation.”


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.